Literature DB >> 19557868

Neuromuscular involvement in various types of Ehlers-Danlos syndrome.

Nicol C Voermans1, Nens van Alfen, Sigrid Pillen, Martin Lammens, Joost Schalkwijk, Machiel J Zwarts, Iris A van Rooij, Ben C J Hamel, Baiel G van Engelen.   

Abstract

OBJECTIVE: Ehlers-Danlos syndrome (EDS) is a clinically and genetically heterogeneous group of heritable connective tissue disorders characterized by joint hypermobility, skin hyperextensibility, and tissue fragility. Muscle involvement is plausible based on recently discovered interactions between muscle cells and extracellular matrix molecules; however, muscle symptoms are only sporadically reported. We designed a cross-sectional study to find out whether neuromuscular features are part of EDS.
METHODS: Standardized questionnaires, physical examination, nerve conduction studies, electromyography, muscle ultrasound, and muscle biopsy were performed in 40 EDS patients with the vascular, classic, tenascin-X (TNX)-deficient type EDS, and hypermobility type of EDS caused by TNXB haploinsufficiency.
RESULTS: Muscle weakness, myalgia, and easy fatigability were reported by the majority of patients. Mild-to-moderate muscle weakness (85%) and reduction of vibration sense (60%) were common. Nerve conduction studies demonstrated axonal polyneuropathy in five patients (13%). Needle electromyography myopathic features in nine patients (26%) and a mixed neurogenic-myopathic pattern in most (60%). Muscle ultrasound showed increased echo-intensity (48%) and atrophy (50%). Mild myopathic features were seen on muscle biopsy of five patients (28%). Overall, patients with the hypermobility type EDS caused by TNXB haploinsufficiency were least affected.
INTERPRETATION: Mild-to-moderate neuromuscular involvement is common in various types of EDS, with a remarkable relation between residual TNX level and degree of neuromuscular involvement, compatible with a dose-effect relation. The findings of this study should increase awareness of neuromuscular symptoms in EDS patients and improve clinical care. They also point to a role of the extracellular matrix in muscle and peripheral nerve function.

Entities:  

Mesh:

Year:  2009        PMID: 19557868     DOI: 10.1002/ana.21643

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  30 in total

1.  Myopathy in a 20-year-old female patient with D4ST-1 deficient Ehlers-Danlos syndrome due to a homozygous CHST14 mutation.

Authors:  N C Voermans; M Kempers; M Lammens; N van Alfen; M C Janssen; C Bönnemann; B G van Engelen; B C Hamel
Journal:  Am J Med Genet A       Date:  2012-03-09       Impact factor: 2.802

Review 2.  Tenascin-X, Congenital Adrenal Hyperplasia, and the CAH-X Syndrome.

Authors:  Walter L Miller; Deborah P Merke
Journal:  Horm Res Paediatr       Date:  2018-05-07       Impact factor: 2.852

Review 3.  Neuromuscular and systemic presentations in adults: diagnoses beyond MERRF and MELAS.

Authors:  Bruce H Cohen
Journal:  Neurotherapeutics       Date:  2013-04       Impact factor: 7.620

4.  Mutations in FKBP14 cause a variant of Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss.

Authors:  Matthias Baumann; Cecilia Giunta; Birgit Krabichler; Franz Rüschendorf; Nicoletta Zoppi; Marina Colombi; Reginald E Bittner; Susana Quijano-Roy; Francesco Muntoni; Sebahattin Cirak; Gudrun Schreiber; Yaqun Zou; Ying Hu; Norma Beatriz Romero; Robert Yves Carlier; Albert Amberger; Andrea Deutschmann; Volker Straub; Marianne Rohrbach; Beat Steinmann; Kevin Rostásy; Daniela Karall; Carsten G Bönnemann; Johannes Zschocke; Christine Fauth
Journal:  Am J Hum Genet       Date:  2012-01-19       Impact factor: 11.025

5.  Novel Nonsense Mutation in SLC39A13 Initially Presenting as Myopathy: Case Report and Review of the Literature.

Authors:  Maja Dusanic; Gabriele Dekomien; Thomas Lücke; Matthias Vorgerd; Joachim Weis; Joerg T Epplen; Cornelia Köhler; Sabine Hoffjan
Journal:  Mol Syndromol       Date:  2018-01-24

6.  Higher fracture prevalence and smaller bone size in patients with hEDS/HSD-a prospective cohort study.

Authors:  T Banica; M Coussens; C Verroken; P Calders; I De Wandele; F Malfait; H-G Zmierczak; S Goemaere; B Lapauw; L Rombaut
Journal:  Osteoporos Int       Date:  2019-12-24       Impact factor: 4.507

7.  Tenascin-X, collagen, and Ehlers-Danlos syndrome: tenascin-X gene defects can protect against adverse cardiovascular events.

Authors:  John W Petersen; J Yellowlees Douglas
Journal:  Med Hypotheses       Date:  2013-07-03       Impact factor: 1.538

8.  Chronic pain in patients with the hypermobility type of Ehlers-Danlos syndrome: evidence for generalized hyperalgesia.

Authors:  Lies Rombaut; Mark Scheper; Inge De Wandele; Janneke De Vries; Mira Meeus; Fransiska Malfait; Raoul Engelbert; Patrick Calders
Journal:  Clin Rheumatol       Date:  2014-02-04       Impact factor: 2.980

9.  Titin-based stiffening of muscle fibers in Ehlers-Danlos Syndrome.

Authors:  Coen A C Ottenheijm; Nicol C Voermans; Bryan D Hudson; Thomas Irving; Ger J M Stienen; Baziel G van Engelen; Henk Granzier
Journal:  J Appl Physiol (1985)       Date:  2012-01-05

10.  Tenascin-X haploinsufficiency associated with Ehlers-Danlos syndrome in patients with congenital adrenal hyperplasia.

Authors:  Deborah P Merke; Wuyan Chen; Rachel Morissette; Zhi Xu; Carol Van Ryzin; Vandana Sachdev; Hwaida Hannoush; Sujata M Shanbhag; Ana T Acevedo; Miki Nishitani; Andrew E Arai; Nazli B McDonnell
Journal:  J Clin Endocrinol Metab       Date:  2013-01-02       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.